Molecular mechanisms of prostate cancer

European Journal of Cancer

Volumn 37, Issue SUPPL. 7, 2001, Pages

  Trapman, Jan ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

CHROMOSOME ABERRATION; GENE EXPRESSION; GENETICS; HUMAN; MALE; ONCOGENE; PROSTATE TUMOR; REVIEW; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; ONCOGENES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0035495496     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)80013-7     Document Type: Article

References (55)

1. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001, 409: 860-922.
2. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001, 291: 1304-1351.
3. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001, 291: 1284-11289.
4. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411: 366-374.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100: 57-70.
6. Landis S, Murray T, Bolden S, Wingo P. Cancer statistics. CA Cancer J Clin 1999, 49: 8-31.
7. Bostwick DG. Prostatic intraepithelial neoplasia (PIN). Urology 1989, 34: 16-22.
8. Carter BS, Bova GS, Beaty TH et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993, 150: 797-802.
9. Tavtigian SV, Simard J, Teng DHF et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nature Gen 2001, 27: 171-180.
10. Pinkel D, Segraves R, Sudar D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Gen 1998, 20: 207-211.
11. Cunningham JM, Shan A, Wick JM et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996, 56: 4475-4482.
12. Cher ML, Bova GS, Moore DH et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996, 56: 3091-3102.
13. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone refractory recurrent prostate carcinoma. Am J Pathol 1998, 153: 141-148.
14. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Gen 1995, 9: 401-406.
15. Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997, 57: 314-319.
16. Bookstein R, Rio P, Madreperia SA et al. P53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993, 53: 3369-3373.
17. Navone N, Troncoso P, Pisters Let al. P53 accumulation and gene mutation in the progression of human prostate cancer. J Natl Cancer Inst 1993, 85: 1657-1669.
18. Visakorpi T, Kallioniemi O-P, Heikkinen A, Koivola T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992, 84: 883-887.
19. Brooks JD, Bova GS, Ewing CM et al. An uncertain role for p53 gene alterations in human prostate cancer. Cancer Res 1996, 56: 3814-3822.
20. Li J, Yen C, Liaw D et al. PTEN a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275: 1943-1947.
21. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999, 96: 4240-4245.
22. Vlietstra RJ, VanAlewijk DC, Hermans KG, VanSteenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998, 58: 2720-2723.
23. Cairns P, Okami K, Halachmi S et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997, 57: 4997-5000.
24. Suzuki H, Freije D, Nusskern DR et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in mutiple metastatic prostate cancer tissues. Cancer Res 1998, 58: 204-209.
25. McMenamin ME. Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high grade Gleason score and advanced stage. Cancer Res 1999, 59: 4291-4296.
26. Nupponen NN, Porkka K, Kakkola L et al. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol 1999, 154: 1777-1783.
27. Reiter RE, Sato J, Thomas G et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chrom Cancer 2000, 27: 95-103.
28. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis. Trends Genet 2000, 16: 168-174.
29. Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Human Mol Genet 2001, 10: 693-698.
30. Graff JR, Konicek BW, McNulty AM et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995, 55: 5195-5199.
31. Lee WH, Morton JI. Epstein JD et al. Cytidine methylation of regulatory sequences near the psi-class glutathione S-transferase gene accompanies prostatic carcinogenesis. Proc Natl Acad Sci US A 1994, 91: 11733-11737.
32. Cordon-Cardo C, Koff A, Drobnjak M et al. Distinct altered patterns of p27kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998, 90: 1284-1291.
33. Schena M, Shalon D, Davis RW and Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270: 467-470.
34. Alizadeh AA, Eisen MB. Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403: 503-511.
35. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83: 851-857.
36. Kuil CW, Berrevoets CA, Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. J Biol Chem 1995, 270: 27659-27576.
37. Brozowski AM, Pike ACW, Dauter Z et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389: 753-758.
38. Riegman PHJ, Vlietstra RJ, VanderKorput JAGM, Romijn JC, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991, 5: 1921-1930.
39. Cleutjens KBJM, VanderKorput HAGM, VanEekelen CCEM, VanRooij HCJ, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997, 11: 148-161.
40. Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ. Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 1996, 7: 1571-1578.
41. Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997, 57: 4511-4516.
42. Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 1998, 273: 20213-20222.
43. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 1999, 13: 376-384.
44. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52: 6940-6944.
45. Nelson PS, Han D, Rochon Y et al. Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics. Electrophoresis 2000, 21: 1823-1831.
46. Xu LL, Su YP, Labiche R et al. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 2001, 92: 322-328.
47. Kantoff P, Giovannucci E, Brown M. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochim Biophys Acta 1998. 1378: C1-C5.
48. Veldscholte J, Ris-Stalpers C, Kuiper GG et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990, 173: 534-540.
49. Taplin ME, Bubley GJ, Ko YJ et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonists. Cancer Res 1999, 59: 2511-2515.
50. Zhao XY, Malloy PJ, Krishnan AV et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nature Med 2000, 6: 703-706.
51. Matias PM, Donner P, Coelho R et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000, 275: 26164-26171.
52. Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994, 54: 5474-5478.
53. Hobisch A, Eder IE, Putz T et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998, 58: 4640-4645.
54. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med 1999, 5: 280-285.
55. Yeh S, Lin HK. Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999, 96: 5438-5463.